Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key idiopathic pulmonary fibrosis (IPF) patient populations, covering…

The dynamics within the LAMA, LABA/LAMA, LABA/ICS FDC, and LABA/LAMA/ICS FDC drug classes will continue to shape the U.S. COPD market, as will the market entry of Verona’s nebulized PDE-3/PDE-4…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key cystic fibrosis patient populations covering 171 countries and more…

Clarivate’s Epidemiology’s coverage of cystic fibrosis (CF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…

Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the availability of LAMAs (e.g., Boehringer…

Clarivate Epidemiology’s coverage of asthma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of asthma for each country, as…